Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Bristol Myers Squibb BMY announced that the FDA has accepted the new drug application (NDA) for its pipeline candidate, iberdomide, in combination with standard therapies (daratumumab and ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

After a broken femur led to a multiple myeloma diagnosis, one patient is raising awareness while specialists point to new treatment options and early detection.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...